{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:56:58Z","timestamp":1790143018123,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T00:00:00Z","timestamp":1487894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T00:00:00Z","timestamp":1487894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We subjected 90 patients covering a biological spectrum of plasma cell dyscrasias (monoclonal gammopathy of undetermined significance (MGUS), amyloid light-chain (AL) amyloidosis and multiple myeloma) to next-generation sequencing (NGS) gene panel analysis on unsorted bone marrow. A total of 64 different mutations in 8 genes were identified in this cohort. <jats:italic>NRAS<\/jats:italic> (28.1%), <jats:italic>KRAS<\/jats:italic> (21.3%), <jats:italic>TP53<\/jats:italic> (19.5%), <jats:italic>BRAF<\/jats:italic> (19.1%) and <jats:italic>CCND1<\/jats:italic> (8.9%) were the most commonly mutated genes in all patients. Patients with non-myeloma plasma cell dyscrasias showed a significantly lower mutational load than myeloma patients (0.91\u00b10.30 vs 2.07\u00b10.29 mutations per case, <jats:italic>P<\/jats:italic>=0.008). <jats:italic>KRAS<\/jats:italic> and <jats:italic>NRAS<\/jats:italic> exon 3 mutations were significantly associated with the myeloma cohort compared with non-myeloma plasma cell dyscrasias (odds ratio (OR) 9.87, 95% confidence interval (CI) 1.07\u201390.72, <jats:italic>P<\/jats:italic>=0.043 and OR 7.03, 95% CI 1.49\u201333.26, <jats:italic>P<\/jats:italic>=0.014). <jats:italic>NRAS<\/jats:italic> exon 3 and <jats:italic>TP53<\/jats:italic> exon 6 mutations were significantly associated with del17p cytogenetics (OR 0.12, 95% CI 0.02\u20130.87, <jats:italic>P<\/jats:italic>=0.036 and OR 0.05, 95% CI 0.01\u20130.54, <jats:italic>P<\/jats:italic>=0.013). Our data show that the mutational landscape reflects the biological continuum of plasma cell dyscrasias from a low-complexity mutational pattern in MGUS and AL amyloidosis to a high-complexity pattern in multiple myeloma. Our targeted NGS approach allows resource-efficient, sensitive and scalable mutation analysis for prognostic, predictive or therapeutic purposes.<\/jats:p>","DOI":"10.1038\/bcj.2017.19","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T14:22:12Z","timestamp":1487946132000},"page":"e537-e537","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Mutational landscape reflects the biological continuum of plasma cell dyscrasias"],"prefix":"10.1038","volume":"7","author":[{"given":"A","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Voigtlaender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Janjetovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Alawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"M\u00e4rz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Radloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Hegenbart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Sch\u00f6nland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,24]]},"reference":[{"key":"BFbcj201719_CR1","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362\u20131369.","journal-title":"N Engl J Med"},{"key":"BFbcj201719_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564\u2013569.","journal-title":"N Engl J Med"},{"key":"BFbcj201719_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K . Multiple myeloma. N Engl J Med 2011; 364: 1046\u20131060.","journal-title":"N Engl J Med"},{"key":"BFbcj201719_CR4","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","volume":"29","author":"G Merlini","year":"2011","unstructured":"Merlini G, Seldin DC, Gertz MA . Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011; 29: 1924\u20131933.","journal-title":"J Clin Oncol"},{"key":"BFbcj201719_CR5","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","volume":"108","author":"G Merlini","year":"2006","unstructured":"Merlini G, Stone MJ . Dangerous small B-cell clones. Blood 2006; 108: 2520\u20132530.","journal-title":"Blood"},{"key":"BFbcj201719_CR6","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1038\/bcj.2016.15","volume":"6","author":"M Binder","year":"2016","unstructured":"Binder M, Rajkumar SV, Ketterling RP, Dispentieri A, Lacy MQ, Gertz MA et al. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J 2016; 6: e401.","journal-title":"Blood Cancer J"},{"key":"BFbcj201719_CR7","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/leu.2013.86","volume":"27","author":"SV Rajkumar","year":"2013","unstructured":"Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 2013; 27: 1738\u20131744.","journal-title":"Leukemia"},{"key":"BFbcj201719_CR8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/ejh.12774","volume":"97","author":"A Mikulasova","year":"2016","unstructured":"Mikulasova A, Smetana J, Wayhelova M, Janyskova H, Sandecka V, Kufova Z et al. Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance. Eur J Haematol 2016; 97: 568\u2013575.","journal-title":"Eur J Haematol"},{"key":"BFbcj201719_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.leukres.2016.03.001","volume":"44","author":"SY Kim","year":"2016","unstructured":"Kim SY, Im K, Park SN, Kim JA, Yoon SS, Lee DS . Burden of cytogenetically abnormal plasma cells in light chain amyloidosis and their prognostic relevance. Leuk Res 2016; 44: 45\u201352.","journal-title":"Leuk Res"},{"key":"BFbcj201719_CR10","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1182\/blood-2010-02-268987","volume":"117","author":"T Bochtler","year":"2011","unstructured":"Bochtler T, Hegenbart U, Heiss C, Benner A, Moos M, Seckinger A et al. Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). Blood 2011; 117: 3809\u20133815.","journal-title":"Blood"},{"key":"BFbcj201719_CR11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1182\/blood-2012-03-412981","volume":"120","author":"BA Walker","year":"2012","unstructured":"Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood 2012; 120: 1077\u20131086.","journal-title":"Blood"},{"key":"BFbcj201719_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014; 25: 91\u2013101.","journal-title":"Cancer Cell"},{"key":"BFbcj201719_CR13","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014; 5: 2997.","journal-title":"Nat Commun"},{"key":"BFbcj201719_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/bjh.13171","volume":"168","author":"KM Kort\u00fcm","year":"2015","unstructured":"Kort\u00fcm KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX et al. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease. Br J Haematol 2015; 168: 507\u2013510.","journal-title":"Br J Haematol"},{"key":"BFbcj201719_CR15","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol 2015; 33: 3911\u20133920.","journal-title":"J Clin Oncol"},{"key":"BFbcj201719_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467\u2013472.","journal-title":"Nature"},{"key":"BFbcj201719_CR17","doi-asserted-by":"publisher","first-page":"717919","DOI":"10.1155\/2014\/717919","volume":"2014","author":"PJ Teoh","year":"2014","unstructured":"Teoh PJ, Chng WJ . p53 abnormalities and potential therapeutic targeting in multiple myeloma. Biomed Res Int 2014; 2014: 717919.","journal-title":"Biomed Res Int"},{"key":"BFbcj201719_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","volume":"3","author":"M Andrulis","year":"2013","unstructured":"Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 2013; 3: 862\u2013869.","journal-title":"Cancer Discov"},{"key":"BFbcj201719_CR19","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/j.clml.2014.06.004","volume":"14","author":"JP Sharman","year":"2014","unstructured":"Sharman JP, Chmielecki J, Morosini D, Palmer GA, Ross JS, Stephens PJ et al. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clin Lymphoma Myeloma Leuk 2014; 14: e161\u2013e163.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFbcj201719_CR20","doi-asserted-by":"publisher","first-page":"7776","DOI":"10.1158\/1078-0432.CCR-11-1791","volume":"17","author":"KD Boyd","year":"2011","unstructured":"Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res 2011; 17: 7776\u20137784.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201719_CR21","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1182\/blood-2007-02-075069","volume":"110","author":"MW Jenner","year":"2007","unstructured":"Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 2007; 110: 3291\u20133300.","journal-title":"Blood"},{"key":"BFbcj201719_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/PAI.0000000000000089","volume":"23","author":"A Mansoor","year":"2015","unstructured":"Mansoor A, Akhter A, Pournazari P, Mahe E, Shariff S, Farooq F et al. Protein expression for novel prognostic markers (cyclins D1, D2, D3, B1, B2, ITG\u03b27, FGFR3, PAX5) correlate with previously reported gene expression profile patterns in plasma cell myeloma. Appl Immunohistochem Mol Morphol 2015; 23: 327\u2013333.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"BFbcj201719_CR23","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.3109\/10428194.2010.496014","volume":"51","author":"BT Ngo","year":"2010","unstructured":"Ngo BT, Felthaus J, Hein M, Follo M, Wider D, Ihorst G et al. Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome. Leuk Lymphoma 2010; 51: 1632\u20131642.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201719_CR24","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B . Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 2014; 30: 2114\u20132120.","journal-title":"Bioinformatics"},{"key":"BFbcj201719_CR25","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1093\/bioinformatics\/btq461","volume":"26","author":"RC Edgar","year":"2010","unstructured":"Edgar RC . Search and clustering orders of magnitude faster than BLAST. Bioinformatics 2010; 26: 2460\u20132461.","journal-title":"Bioinformatics"},{"key":"BFbcj201719_CR26","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1101\/gr.229202","volume":"12","author":"WJ Kent","year":"2002","unstructured":"Kent WJ . BLAT\u2014the BLAST-like alignment tool. Genome Res 2002; 12: 656\u2013664.","journal-title":"Genome Res"},{"key":"BFbcj201719_CR27","doi-asserted-by":"crossref","first-page":"24205","DOI":"10.18632\/oncotarget.4434","volume":"6","author":"M Lionetti","year":"2015","unstructured":"Lionetti M, Barbieri M, Todoerti K, Agnelli L, Marzorati S, Fabris S et al. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget 2015; 6: 24205\u201324217.","journal-title":"Oncotarget"},{"key":"BFbcj201719_CR28","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3324\/haematol.2010.023697","volume":"95","author":"L Lod\u00e9","year":"2010","unstructured":"Lod\u00e9 L, Eveillard M, Trichet V, Soussi T, Wuilleme S, Richebourg S et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 2010; 95: 1973\u20131976.","journal-title":"Haematologica"},{"key":"BFbcj201719_CR29","doi-asserted-by":"publisher","first-page":"21353","DOI":"10.18632\/oncotarget.7241","volume":"7","author":"M Lionetti","year":"2016","unstructured":"Lionetti M, Barbieri M, Manzoni M, Fabris S, Bandini C, Todoerti K et al. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature. Oncotarget 2016; 7: 21353\u201321361.","journal-title":"Oncotarget"},{"key":"BFbcj201719_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/sj.leu.2404524","volume":"21","author":"WJ Chng","year":"2007","unstructured":"Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E et al. Clinical significance of TP53 mutation in myeloma. Leukemia 2007; 21: 582\u2013584.","journal-title":"Leukemia"},{"key":"BFbcj201719_CR31","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/leu.2014.13","volume":"28","author":"L Melchor","year":"2014","unstructured":"Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MF et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia 2014; 28: 1705\u20131715.","journal-title":"Leukemia"},{"key":"BFbcj201719_CR32","first-page":"3","volume":"25","author":"KC Anderson","year":"2011","unstructured":"Anderson KC . Multiple myeloma: a clinical overview. Oncology (Williston Park) 2011; 25: 3\u20139.","journal-title":"Oncology (Williston Park)"},{"key":"BFbcj201719_CR33","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/j.clml.2016.02.025","volume":"16","author":"B Fakhri","year":"2016","unstructured":"Fakhri B, Vij R . Clonal evolution in multiple myeloma. Clin Lymphoma Myeloma Leuk 2016; 16: S130\u2013S134.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201719","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T17:23:43Z","timestamp":1671729823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,24]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2]]}},"alternative-id":["BFbcj201719"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2017.19","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,24]]},"assertion":[{"value":"12 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}